Medications to Reduce Breast Cancer Risk: Promise and Limitations

Lydia E Pace^{1

2}, Nancy L Keating^{2

3}

Affiliations

¹ Division of Women's Health, Brigham and Women's Hospital, Boston, Massachusetts.
² Division of General Internal Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
³ Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts.

Editorial

Lydia E Pace et al. JAMA. 2019.

. 2019 Sep 3;322(9):821-823.

doi: 10.1001/jama.2019.9689.

Lydia E Pace^{1

2}, Nancy L Keating^{2

3}

¹ Division of Women's Health, Brigham and Women's Hospital, Boston, Massachusetts.
² Division of General Internal Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
³ Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts.

No abstract available

Comment on

Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Nelson HD, Fu R, Zakher B, Pappas M, McDonagh M. Nelson HD, et al. JAMA. 2019 Sep 3;322(9):868-886. doi: 10.1001/jama.2019.5780. JAMA. 2019. PMID: 31479143
Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task Force Recommendation Statement.
US Preventive Services Task Force; Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, Doubeni CA, Epling JW Jr, Kubik M, Landefeld CS, Mangione CM, Pbert L, Silverstein M, Tseng CW, Wong JB. US Preventive Services Task Force, et al. JAMA. 2019 Sep 3;322(9):857-867. doi: 10.1001/jama.2019.11885. JAMA. 2019. PMID: 31479144